Literature DB >> 19139291

Activity of anidulafungin in a murine model of Candida krusei infection: evaluation of mortality and disease burden by quantitative tissue cultures and measurement of serum (1,3)-beta-D-glucan levels.

Luis Ostrosky-Zeichner1, Victor L Paetznick, Jose Rodriguez, Enuo Chen, Daniel J Sheehan.   

Abstract

Experience with anidulafungin against Candida krusei is limited. Immunosuppressed mice were injected with 1.3 x 10(7) to 1.5 x 10(7) CFU of C. krusei. Animals were treated with saline, 40 mg/kg fluconazole, 1 mg/kg amphotericin B, or 10 and 20 mg/kg anidulafungin for 5 days. Anidulafungin improved survival and significantly reduced the number of CFU/g in kidneys and serum beta-glucan levels.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19139291      PMCID： PMC2663062          DOI： 10.1128/AAC.00955-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  20 in total

Review 1.  Echinocandins: role in antifungal therapy, 2005.

Authors:  Aimee K Zaas; Barbara D Alexander
Journal:  Expert Opin Pharmacother       Date:  2005-08       Impact factor: 3.889

2.  Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans.

Authors:  Luis Ostrosky-Zeichner; Barbara D Alexander; Daniel H Kett; Jose Vazquez; Peter G Pappas; Fumihiro Saeki; Paul A Ketchum; John Wingard; Robert Schiff; Hiroshi Tamura; Malcolm A Finkelman; John H Rex
Journal:  Clin Infect Dis       Date:  2005-07-21       Impact factor: 9.079

Review 3.  Invasive Candida infections: the changing epidemiology.

Authors:  Kieren A Marr
Journal:  Oncology (Williston Park)       Date:  2004-12       Impact factor: 2.990

4.  In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera.

Authors:  Nathan P Wiederhold; Laura K Najvar; Rosie Bocanegra; Destiny Molina; Marcos Olivo; John R Graybill
Journal:  Antimicrob Agents Chemother       Date:  2007-02-16       Impact factor: 5.191

5.  International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia.

Authors:  L Ostrosky-Zeichner; D Kontoyiannis; J Raffalli; K M Mullane; J Vazquez; E J Anaissie; J Lipton; P Jacobs; J H Jansen van Rensburg; J H Rex; W Lau; D Facklam; D N Buell
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-10       Impact factor: 3.267

Review 6.  Emerging fungal diseases.

Authors:  Marcio Nucci; Kieren A Marr
Journal:  Clin Infect Dis       Date:  2005-07-11       Impact factor: 9.079

7.  Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial.

Authors:  Ernst-Rüdiger Kuse; Ploenchan Chetchotisakd; Clovis Arns da Cunha; Markus Ruhnke; Carlos Barrios; Digumarti Raghunadharao; Jagdev Singh Sekhon; Antonio Freire; Venkatasubramanian Ramasubramanian; Ignace Demeyer; Marcio Nucci; Amorn Leelarasamee; Frédérique Jacobs; Johan Decruyenaere; Didier Pittet; Andrew J Ullmann; Luis Ostrosky-Zeichner; Olivier Lortholary; Sonja Koblinger; Heike Diekmann-Berndt; Oliver A Cornely
Journal:  Lancet       Date:  2007-05-05       Impact factor: 79.321

8.  Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.

Authors:  Peter G Pappas; Coleman M F Rotstein; Robert F Betts; Marcio Nucci; Deepak Talwar; Jan J De Waele; Jose A Vazquez; Bertrand F Dupont; David L Horn; Luis Ostrosky-Zeichner; Annette C Reboli; Byungse Suh; Raghunadharao Digumarti; Chunzhang Wu; Laura L Kovanda; Leah J Arnold; Donald N Buell
Journal:  Clin Infect Dis       Date:  2007-08-29       Impact factor: 9.079

9.  Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005.

Authors:  M A Pfaller; D J Diekema; D L Gibbs; V A Newell; E Nagy; S Dobiasova; M Rinaldi; R Barton; A Veselov
Journal:  J Clin Microbiol       Date:  2007-12-12       Impact factor: 5.948

10.  Anidulafungin versus fluconazole for invasive candidiasis.

Authors:  Annette C Reboli; Coleman Rotstein; Peter G Pappas; Stanley W Chapman; Daniel H Kett; Deepali Kumar; Robert Betts; Michele Wible; Beth P Goldstein; Jennifer Schranz; David S Krause; Thomas J Walsh
Journal:  N Engl J Med       Date:  2007-06-14       Impact factor: 91.245
View more
  4 in total

Review 1.  Echinocandin antifungal drugs in fungal infections: a comparison.

Authors:  Sharon C-A Chen; Monica A Slavin; Tania C Sorrell
Journal:  Drugs       Date:  2011-01-01       Impact factor: 9.546

2.  In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies.

Authors:  Emilia Cantón; Javier Pemán; Amparo Valentín; Ana Espinel-Ingroff; Miguel Gobernado
Journal:  Antimicrob Agents Chemother       Date:  2009-04-20       Impact factor: 5.191

3.  Activity of anidulafungin in a murine model of Candida krusei infection: evaluation of mortality and disease burden by quantitative tissue cultures and measurement of serum (1,3)-beta-D-glucan levels.

Authors:  Luis Ostrosky-Zeichner; Victor L Paetznick; Jose Rodriguez; Enuo Chen; Daniel J Sheehan
Journal:  Antimicrob Agents Chemother       Date:  2009-01-12       Impact factor: 5.191

4.  Antifungal efficacy during Candida krusei infection in non-conventional models correlates with the yeast in vitro susceptibility profile.

Authors:  Liliana Scorzoni; Maria Pilar de Lucas; Ana Cecilia Mesa-Arango; Ana Marisa Fusco-Almeida; Encarnación Lozano; Manuel Cuenca-Estrella; Maria Jose Mendes-Giannini; Oscar Zaragoza
Journal:  PLoS One       Date:  2013-03-28       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.